8-K: STRATA Skin Sciences Reports Mixed Q3 Results, Achieves First Operating Profit Since 2018

STRATA Skin Sciences reported a slight year-over-year revenue decrease but achieved its first operating profit since 2018 in the third quarter of 2024, driven by improved gross margins and reduced operating expenses.

Summary

• STRATA Skin Sciences announced its financial results for the third quarter of 2024, showing a revenue of $8.8 million, a slight decrease from $8.9 million in the same quarter of 2023.
• Global net recurring revenue increased to $5.4 million, up from $5.3 million year-over-year.
• Gross domestic XTRAC recurring billings were $4.8 million, a slight decrease from $4.9 million in the prior year.
• Revenue per domestic XTRAC system increased to $5,332, up from $5,233 year-over-year, despite a decrease in the number of systems.
• The company achieved a non-GAAP operating profit of $128,000, the first since its major refinancing in 2018, after adjusting for a one-time $1.8 million tax accrual.
• The domestic installed base of XTRAC devices decreased to 873, while the TheraClearX device base increased to 135.
• A registered direct offering in July 2024 raised $2.1 million through the sale of 665,136 shares at an average price of $3.16 per share.
• The company received approval for the XTRAC Momentum 1.0 device in Japan and has begun commercial rollout.
• Gross margin improved to 60.3% in the third quarter, up from 56.0% in the same period last year.
• Total operating expenses decreased to $5.2 million, down from $5.6 million year-over-year.
• The net loss for the quarter was $0.3 million, or $0.08 per share, compared to a net loss of $1.1 million, or $0.30 per share, in the third quarter of 2023.

Sentiment

Score: 7

Explanation: The document shows a positive turnaround with the company achieving its first operating profit since 2018 and improving key financial metrics. However, there are still some challenges, such as a slight decrease in overall revenue and a net loss for the quarter, which temper the overall sentiment.

Positives

• The company achieved its first operating profit since 2018, indicating a significant turnaround.
• Revenue per XTRAC system increased, showing improved utilization and pricing.
• Gross margin improved significantly, demonstrating better cost management.
• Operating expenses decreased, contributing to improved profitability.
• The company successfully raised capital through a direct offering.
• TheraClearX device placements are growing, indicating market acceptance.
• The company is seeing success with its direct-to-consumer marketing efforts.
• The XTRAC device has been approved in Japan, expanding its market reach.

Negatives

• Overall revenue decreased slightly year-over-year.
• Domestic XTRAC recurring billings decreased slightly year-over-year.
• The domestic installed base of XTRAC devices decreased, indicating some loss of accounts.
• The company recorded a net loss of $0.3 million for the quarter, although it is a significant improvement from the previous year.
• The company incurred a one-time expense of $1.8 million related to a New York state tax audit.

Risks

• The company faces competition in the laser device market, as evidenced by the lawsuit against LaserOptek.
• The company's reliance on recurring revenue from XTRAC devices makes it vulnerable to changes in healthcare reimbursement policies.
• The company's ability to maintain its current growth trajectory depends on its ability to continue to expand its direct-to-consumer marketing efforts.
• The company's financial performance is subject to various economic and market risks.

Future Outlook

The company aims to achieve profitability and sustainable cash flow generation through its multifaceted strategy, including direct-to-consumer marketing and maximizing the utilization of its XTRAC devices. The company believes the recent equity raise and improved operating performance will help achieve this goal.

Management Comments

• The 2% year-over-year increase in revenue per XTRAC system in the third quarter of 2024 illustrates progress in the Company's turnaround.
• This metric, along with essentially flat year-over-year revenue and global net recurring revenue in the third quarter, points to additional evidence that our business has stabilized.
• Gross margin as a percent of revenue continued to strengthen for the third consecutive quarter, reaching 60.3% in the third quarter.
• Altogether, these trends allowed us to generate a non-GAAP operating profit in the third quarter of 2024, the first time since 2018 that this has occurred.
• Our DTC efforts remain a key focus of our turnaround strategy, and we continue to see signs of execution on this front.
• We continue to examine our installed base of XTRAC devices in an effort to maximize their utilization.
• The combination of our renewed DTC marketing efforts and our efforts to maximize utilization of our XTRAC devices with our dermatology partners helped us achieve the highest quarterly average revenue per device from our XTRAC installed base since the end of 2022.
• This financing, along with continued improving operating and financial performance, should help lead us to profitability and sustainable cash flow generation, which was the goal of our multifaceted strategy put in motion at the beginning of 2024.

Industry Context

The announcement reflects a competitive landscape in the medical device industry, particularly in dermatology, where companies are focused on innovative treatments and recurring revenue models. The legal action against LaserOptek highlights the importance of intellectual property and fair competition in this sector. The company's focus on direct-to-consumer marketing aligns with a broader trend in healthcare where companies are increasingly engaging directly with patients.

Comparison to Industry Standards

• While STRATA's revenue growth is modest, the improvement in gross margin to 60.3% is a positive sign, indicating better cost management compared to some competitors in the medical device space.
• Companies like Cynosure and Cutera, which also operate in the aesthetic laser market, often report gross margins in the 50-60% range, making STRATA's performance competitive.
• The increase in revenue per XTRAC system is a key metric, as it shows improved utilization of existing assets, which is crucial for companies with recurring revenue models. This is similar to how companies like InMode focus on maximizing the utilization of their installed base.
• The successful capital raise of $2.1 million is a positive step, but it is relatively small compared to larger players in the industry. Companies like Syneron Candela often raise significantly larger amounts to fund growth and acquisitions.
• The legal action against LaserOptek is not uncommon in the medical device industry, where intellectual property is highly valued. Similar lawsuits have been seen between companies like Allergan and Revance, highlighting the competitive nature of the market.

Management Changes

Legal Proceedings

• The company filed a complaint against LaserOptek, Monarch Laser Services, and The Pinnacle Health Group, citing unfair competition.
• A court order was entered on November 8, 2024, enjoining LaserOptek and The Pinnacle Group from making false or misleading statements about their Pallas lasers and STRATA's lasers.

Stakeholder Impact

• Shareholders will be encouraged by the company's improved financial performance and the achievement of operating profit.
• Employees may benefit from the company's improved financial stability and growth prospects.
• Customers may benefit from the company's continued investment in innovative dermatological treatments.
• Suppliers may benefit from the company's increased sales and production.

Next Steps

• The company will continue to focus on its direct-to-consumer marketing efforts.
• The company will continue to maximize the utilization of its XTRAC devices.
• The company will continue to expand the market for its TheraClearX devices.
• The company will continue the commercial rollout of the XTRAC Momentum 1.0 device in Japan.

Key Dates

Keywords

STRATA Skin Sciences, XTRAC, TheraClearX, dermatology, laser, medical devices, recurring revenue, operating profit, financial results, acne, psoriasis, vitiligo